【Nikkei Plunge】Asia Development 5 Yen JAL Plunge SDSHD SanBio❗️
SBI Biotech is a biotech venture developing regenerative cell drugs for central nervous system diseases, and while its near-term results show substantial losses, market interest is focused on the development of the regenerative cell drug "SB623," which is believed to have a large potential market. In the midst of this, after the market close on the 7th, the company announced that it had filed with the Ministry of Health, Labour and Welfare for manufacturing and sales approval for domestic SB623 chronic traumatic brain injury program. As this information is viewed as a positive factor, investment funds are once again stepping in with expectations for upside.
× ![]()